98.1% of the patients that were classified into the responders group presented a decrease in the pain scales and in the total number of administered drugs 3-6 months after having our test.
InSyBio Precision Chronic Pain Treatment Tool has been developed for the US population, and is mainly intended for use in the US. All medical decisions need to be taken by a patient in consultation with their doctor. The authors and the sponsors of this tool accept no responsibility for clinical use or misuse of the machine learning empowered prognostic scores or any other detail displayed in our tool.
The predictions are based on InSyBio's machine learning models whose initial training and evaluation has been conducted on data from the OPERA study. Prediction models have currently been evaluated in 632 patients with an accuracy of discriminating between responders and non-responders of 81.7%.
Form more details on the OPERA study read the following articles:
- Gudin, J., Mavroudi, S., Korfiati, A., Theofilatos, K., Dietze, D., & Hurwitz, P. (2020). Reducing Opioid Prescriptions by Identifying Responders on Topical Analgesic Treatment Using an Individualized Medicine and Predictive Analytics Approach. Journal of Pain Research, 13, 1255-1266.
- Gudin JA, Brennan MJ, Harris ED, et al. Changes in pain and concurrent pain medication use following compounded topical analgesic treatment for chronic pain: 3- and 6-month follow-up results from the prospective, observational Optimizing Patient Experience and Response to Topical Analgesics study. J Pain Res. 2017;10:2341.
- Gudin JA, Brennan MJ, Harris ED, Hurwitz PL, Dietze DT, Strader JD. Reduction of opioid use and improvement in chronic pain in opioid-experienced patients after topical analgesic treatment: an exploratory analysis. Postgrad Med. 2018;130(1):42-51.